Q-fever post-vaccination study

Completed

• Conditions: Coxiella burnetii infection; Q-fever; 10004018

• Registration Number: NL-OMON35763
• Lead Sponsor: RIVM

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

- Signed Informed Consent
- willing to adhere to blood draw schedule
- has taken part in the national Q-fever vaccination campaign

Exclusion Criteria

none

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Humoral immune response: IgG and IgM antibodies against fase 1 and 2 antigens<br /><br>of C. burnetii are measured by means of several serological tests:: immune<br /><br>fluorescence assay (IFA), enzyme-linked immuno sorbent assay (ELISA),<br /><br>complement binding reaction (CBR), polymerase chain reaction (PCR) and<br /><br>micro-array.<br /><br>Cellular immune response:<br /><br>After stimulation of whole blood, the levels of interferon-gamma (IFN-gamma),<br /><br>interleukine (IL)-10 and possibly IL-12 production are measured. Also a<br /><br>T-helper 1 and T-helper 2 cytokine profile are measured in isolated mononuclear<br /><br>cells, isolated CD14+ monocytes and isolated T-cells after stimulation, and<br /><br>differentiation of the cells is studied.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>